AstraZeneca to adopt Schrödinger's molecule-modeling platform for drug discovery

A new deal with AstraZeneca comes as Schrödinger aims to move into the clinic itself with wholly owned assets focused on at least three oncology targets. (AstraZeneca)

AstraZeneca has begun working with Schrödinger to incorporate its machine learning and molecule-modeling platform within its drug discovery work, soon after the computing company received a preclinical milestone payment through its collaboration with Sanofi.

Schrödinger’s platform aims to predict how strongly a potential drug will bind and affect a target protein with the goal of optimizing its chemical properties and reducing the number of compounds that need to be synthesized before settling on a lead candidate.

AstraZeneca’s researchers hope to use the programs to identify new therapeutics, while Schrödinger’s staff will work to integrate the platform within the drugmaker’s workflows and share best practices, according to the companies. Financial details were not disclosed.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Our strategic goal is to transform drug design using innovative digital technologies,” AstraZeneca’s global chemistry R&D lead Garry Pairaudeau said in a statement. “In this collaboration with Schrödinger, we look forward to realizing the potential of predictive physics-based modeling and machine learning to help us deliver higher quality compounds more effectively.”

RELATED: Schrödinger raises more cash, amassing $110M for R&D drive

The deal comes as Schrödinger aims to move into the clinic itself with wholly owned assets focused on at least three oncology targets. This past summer, the company brought on translational science veterans from Merck and Eisai to help move its programs out of the discovery phase, after raising a total of $110 million to support its internal efforts and a dedicated staff.

Previously, New York-based Schrödinger has focused on bringing digital expertise to the biopharma R&D programs of several other companies and affiliates—including a multiyear, multitarget collaboration with Sanofi, which advanced its second drug discovery program this past July with Schrödinger providing molecular simulation from target analysis to lead identification. Earlier this year, the companies announced the advancement of a separate program in autoimmune disease into clinical trials.

RELATED: Schrödinger, WuXi launch virtual drug discovery JV

Schrödinger counts more than two dozen potential therapies in a range of disease areas currently being developed through its collaborations, including several clinical-stage assets and two FDA-approved cancer treatments.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.